Recent Articles

FDA Clears Wider Use of Cooling Cap to Reduce Hair Loss during Chemotherapy

| July 21, 2017 | 0 Comments

FDA Clears Wider Use of Cooling Cap to Reduce Hair Loss during Chemotherapy The FDA has cleared a cooling cap—a device designed to reduce hair loss during chemotherapy called the DigniCap Scalp Cooling System—for use by patients with any type of solid tumor. See Original Article

Continue Reading

Two-Drug Combination Approved for Lung Cancers with BRAF Mutations

| July 18, 2017 | 0 Comments

Two-Drug Combination Approved for Lung Cancers with BRAF Mutations FDA approved the combination of dabrafenib (Tafinlar®) and trametinib (Mekinist®) for patients the treatment of metastatic non-small cell lung cancer (NSCLC) that has an alteration in the BRAF gene called the V600E mutation.See Original Article

Continue Reading

NCI’s Technology Transfer Center—Moving Inventions and Ideas from the Lab to Patients: An Interview with Dr. Michael Salgaller

| July 17, 2017 | 0 Comments

NCI’s Technology Transfer Center—Moving Inventions and Ideas from the Lab to Patients: An Interview with Dr. Michael Salgaller An interview with Dr. Michael Salgaller about how NCI’s Technology Transfer Center helps to move new technologies developed by NCI and NIH scientists from the lab to the bedside.See Original Article

Continue Reading

New Rituximab Formulation Approved for Some Lymphomas, Leukemia

| July 14, 2017 | 0 Comments

New Rituximab Formulation Approved for Some Lymphomas, Leukemia The FDA has approved a new formulation of rituximab, Rituxan Hycela, that reduces treatment administration time for patients with several types of blood cancer. See Original Article

Continue Reading

Large Study Verifies Cancer Risk for Women Carrying BRCA1 or BRCA2 Mutations

| July 12, 2017 | 0 Comments

Large Study Verifies Cancer Risk for Women Carrying BRCA1 or BRCA2 Mutations Results from the first large prospective study of breast and ovarian cancer risk in women with inherited mutations in the BRCA 1 or BRCA2 genes confirm the high risks estimated from earlier, retrospective studies.See Original Article

Continue Reading

NCI's CURE Program—21 Years of Increasing Diversity in the Biomedical Workforce

| July 11, 2017 | 0 Comments

NCI's CURE Program—21 Years of Increasing Diversity in the Biomedical Workforce NCI’s CURE program recently celebrated its 21st anniversary of providing training and other support to improve the diversity of people involved in cancer research and care. See Original Article FDA Approves Talimogene Laherparepvec to Treat Metastatic Melanoma The FDA has approved the first oncolytic […]

Continue Reading

NCI's CURE Program—21 Years of Addressing Diversity in the Oncology Workforce

| July 10, 2017 | 0 Comments

NCI's CURE Program—21 Years of Addressing Diversity in the Oncology Workforce NCI’s CURE program recently celebrated its 21st anniversary of providing training and other support to improve the diversity of people involved in cancer research and care. See Original Article January Monthly Spotlight: Cervical Health and Cervical Cancer Disparities In January, CRCHD joins the nation […]

Continue Reading

Program Spotlight: Partnership for the Advancement of Cancer Research Project Brings Cancer Research Training to Underrepresented Students at New Mexico State University

| July 10, 2017 | 0 Comments

Program Spotlight: Partnership for the Advancement of Cancer Research Project Brings Cancer Research Training to Underrepresented Students at New Mexico State University The NMSU and FHCRC PACHE partnership is making progress in recruiting and training Native Americans and Hispanics for careers in cancer research and drawing attention to the importance of cancer health disparities research.See […]

Continue Reading

Grantee Spotlight: Julie Dang, M.P.H. – Personalizing Outreach to Address Asian Cancer Health Disparities

| July 9, 2017 | 0 Comments

Grantee Spotlight: Julie Dang, M.P.H. – Personalizing Outreach to Address Asian Cancer Health Disparities See Original Article Keeping Pace: How New Data Can Affect Ongoing Clinical Trials Research results sometimes outrace the design of an ongoing clinical trial and the trial has to be recalibrated to include newer treatments, according to NCI’s Dr. Jo Anne […]

Continue Reading

Persistent Peripheral Neuropathy Increases Fall Risk among Cancer Survivors

| July 8, 2017 | 0 Comments

Persistent Peripheral Neuropathy Increases Fall Risk among Cancer Survivors Many female cancer survivors have problems with mobility and other physical functioning as a result of persistent peripheral neuropathy caused by chemotherapy treatment, according to a new study. See Original Article Most American Adults Do Not Use Sunscreen Regularly The majority of Americans are not using […]

Continue Reading